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Background: Preterm prelabor rupture of membrane (PPROM) causes maternal and neonatal complications.
Prophylactic antiobiotics were used in the management of PPROM. The objectives of this retrospective study were
to compare clinical course and outcome of PPROM managed expectantly with prophylactic antibiotics and
antenatal corticosteroids with those without prophylactic antibiotics and antenatal corticosteroids.
Results: A total of 170 cases of singleton pregnant women with gestational age between 28–34 weeks suffering
from PROM during January 1998 to December 2009 were included; 119 cases received prophylactic antibiotics and
antenatal corticosteroids while 51 cases did not received prophylactic antibiotics and antenatal corticosteroids.
Median latency period in the study group was significantly longer than in the control group (89.8 vs. 24.3 hours,
P < 0.001). The percentage of patients who did not deliver within 48 hours and within 7 days in the study group
were also significantly higher than in control group (64.7 vs. 31.4%, P < 0.001 and 29.4 vs. 7.8%, P = 0.002,
respectively). Maternal infectious morbidity was comparable between groups (17.6% vs. 13.7%, P = 0.52). Neonatal
infectious morbidity was significantly lesser in study group than control group (21% vs. 35.3%, p = 0.04).
Conclusions: Latency period of PPROM after using prophylactic antibiotics and antenatal corticosteroids increased
while neonatal infectious morbidity was low. But maternal infectious morbidity was not increased. This retrospective
study confirms the benefit of prophylactic antibiotics and antenatal corticosteroids in management of PPROM.
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Prelabor or premature rupture of membranes is defined
as rupture of membranes before onset of labor [1]. Pre-
term prelabor rupture of membrane (PPROM) is prela-
bor rupture of membranes that occurs before 37 weeks
gestation. PPROM usually results in preterm birth and
causes 1/3 of preterm birth. PPROM causes complica-
tions not only in the neonate but also in the mother [1].
These complications are more common in PPROM of
less than 34 weeks gestation [2].
In the past, management of women with PPROM was
expectant without any medications. Several studies
reported that the latency period after PPROM was 1.5-
4.6 days [3-5]. Fifty to ninety-three percent cases and
69.3-97.3% cases delivered within 48 hours and 7 days
following rupture of membranes, respectively [3-7].* Correspondence: vorapong.p@chula.ac.th
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distribution, and reproduction in any mediumAfter two large randomized controlled trials, prolonga-
tion of latency period is believed to reduce neonatal
complications [8,9]. Thus, the American College of
Obstetricians and Gynecologists (ACOG) prepares clin-
ical management guidelines and recommends using
prophylactic antibiotics in the expectant management of
PPROM to prolong pregnancy, reduce maternal infectious
morbidity and reduce infectious and gestational age-
dependent neonatal morbidity. Corticosteroids are recom-
mended to administer in PPROM to reduce the risks of
neonatal prematurity related complications [10,11].
There have been a few reports of the clinical course and
outcome of PPROM after using prophylactic antibiotics
and antenatal corticosteroids. Therefore we retrospectively
reviewed and compared the latency period, maternal and
neonatal morbidity and mortality in patients with PPROM
managed expectantly with prophylactic antibiotics and
antenatal corticosteroids and without prophylactic anti-
biotics and antenatal corticosteroids.d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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This study was approved by the Research Ethics Com-
mittee of the Faculty of Medicine, Chulalongkorn Uni-
versity, Bangkok, Thailand. Medical records of pregnant
women with gestational age (GA) between 28–34
complete weeks with PROM admitted to the Depart-
ment of Obstetrics and Gynecology, Faculty of Medicine,
Chulalongkorn University, Bangkok, Thailand between
January 1997 and December 2009 were reviewed. Single-
ton pregnancies with cervical dilatation less than 4 cm.
at admission were reviewed. From year 1998–2009, only
women who received prophylactic antibiotics to prolong
latency period and had a single course of antenatal corti-
costeroids to induce fetal lung maturity were included
into study group. Two-day’s intravenous ampicillin and
oral macrolide (erythromycin, roxithromycin or azithro-
mycin) followed by five days oral amoxicillin and oral
macrolide (erythromycin, roxithromycin or azithromy-
cin) were used as prophylactic antibiotics. In year 1997,
women who were managed expectantly without prophy-
lactic antibiotics and antenatal corticosteroids were
included as a control group. We excluded cases that had
fetal anomaly or any conditions that would require the
pregnancy to be terminated upon admission including
chorioamnionitis or fetal distress. Cases that received
tocolysis were also excluded. Diagnosis of PPROM was
based on a combination of history, gross leakage of am-
niotic fluid, ferning test, nile blue test and oligohydram-
nios by ultrasonogram. Latency period was defined as
the time interval between the rupture of membranes and
delivery. Omphalitis was defined as a localized infection
of the umbilical cord stump [12].
Data on maternal age, gravidity, parity, total number
of antenatal care visits, GA at admission, latency period,
GA at delivery, mode of delivery, maternal and neonatal
outcomes, and duration of hospitalization were extracted
from the medical records of the patients. Demographic
characteristics, latency period, maternal and neonatal







Total number of antenatal care visits 5.1 ±
GA at admission (weeks) 31.7 ±
Median (interquartile) GA at admission (weeks) 32 (3
Data presented as mean ± SD or n (%).
GA: gestational age.
* Mann–Whitney U test was used.Statistical analysis
Statistical analysis was performed with SPSS software
package version 12.0 (SPSS Inc, Chicago, IL, USA). Data
was presented as mean± standard deviation (SD), me-
dian and percentage. Continuous variables were com-
pared by student t test and Mann–Whitney U test while
chi square test, or Fisher exact test when appropriate,
was used to compare categorical variables. A P-value <
0.05 was considered statistically significant.
Results
A total of 170 cases of PPROM were included; 119 cases
received prophylactic antibiotics and antenatal corticos-
teroids (study group) while 51 cases did not received
prophylactic antibiotics and antenatal corticosteroids
(control group). Demographic characteristics are shown
in Table 1. There were no statistical differences between
study and control groups for age, parity, total number of
antenatal care visits and GA at admission.
Clinical course and maternal morbidity are shown in
Table 2. Median latency period in the study group was
significantly longer than in control group (89.8 vs.
24.3 hours, P < 0.001). The percentage of patients who
did not deliver within 48 hours and within 7 days in the
study group were also significantly higher than in con-
trol group (64.7% vs. 31.4%, P < 0.001 and 29.4% vs.
7.8%, P = 0.002, respectively). The number of pregnancy
that reached 34 weeks were 31 (26.1%) and 15 (29.4%) in
the study and control group, respectively (P = 0.07). And
the number of pregnancy that reached 37 weeks were 1
(0.8%) and 0 (0%) in the study and control group, re-
spectively (P = 1.00). GA at delivery was comparable.
Median day of hospitalization in study group was signifi-
cantly longer than in control group. Maternal infectious
morbidity such as chorioamnionitis, postpartum metritis
and surgical wound infections were comparable between
groups. There was no maternal death in both groups.
Neonatal outcome is shown in Table 3. There were no
significant differences between study and control groupsy group Control group P value
19) (n = 51)




2.5 4.8 ± 0.6 0.39
1.6 31.8 ± 2.2 0.74
1, 33) 32 (30, 34) 0.22*
Table 2 Clinical course and maternal morbidity between groups
Study group (n = 119) Control group (n = 51) P value
Latency periods (hours) median (interquartile) 89.8 (26, 175.3) 24.3 (8.4, 60.3) < 0.001
> 2 days 77 (64.7%) 16 (31.4%) < 0.001
> 7 days 35 (29.4%) 4 (7.8%) 0.002
GA at delivery (weeks) 32.5 ± 1.9 31.9 ± 2.2 0.80
Mode of delivery 0.30
- Vaginal delivery 82 (68.9%) 31 (60.8%)
- Forceps & vacuum extraction 3 (2.5%) 1 (2%)
- Cesarean section 31 (26.1%) 15 (29.4%)
- Breech assisting 3 (2.5%) 4 (7.8%)
Maternal infectious morbidity 21 (17.6%) 7 (13.7%) 0.52
- Chorioamnionitis 19 6
- Metritis 1 1
- Wound infection 1 0
Median day of hospitalization (interquartile) 8 (5, 12) 4 (2, 6) < 0.001
Data presented as median (interquartile), mean ± SD or n (%).
GA: gestational age.
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hospitalization, neonatal intensive care unit (NICU) stay,
and ventilation assistance. Rates of respiratory distress
syndrome (RDS), intraventricular hemorrhage (IVH),
necrotizing enterocolitis (NEC) and neonatal mortalityTable 3 Neonatal outcomes between groups
Character Study group (n = 119)
Sex
- Male 80 (67.2%)
- Female 39 (32.8%)
Birth weight (grams) 1944.7 ± 427.4
Apgar scores
At 1 minute < 7 22 (18.5%)
At 5 minutes < 7 5 (4.2%)










NICU stay 38 (31.9%)
Ventilation assistance 16 (13.4%)
Mortality 2 (1.7%)
Data presented as mean ± SD, median (interquartile) or n (%).
RDS: respiratory distress syndrome, IVH: intraventricular hemorrhage, NEC: necrotizinwere not significantly different between both groups.
Neonatal infectious morbidity including sepsis, pneumo-
nia, meningitis, and omphalitis were significantly less in
the study group than in control group (21% vs. 35.3%,




1896.3 ± 419.8 0.49
8 (15.7%) 0.83
2 (3.9%) 0.58












g enterocolitis, NICU: neonatal intensive care unit.
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This retrospective study compared clinical course and
outcome of PPROM cases managed expectantly with
prophylactic antibiotics and antenatal corticosteroids
with those without prophylactic antibiotics and antenatal
corticosteroids. Latency period was significantly longer
in PPROM cases managed expectantly with prophylactic
antibiotics and antenatal corticosteroids. Neonatal infec-
tious morbidity was significantly lesser in cases managed
expectantly with prophylactic antibiotics and antenatal
corticosteroids. But maternal infectious morbidity was
comparable. This finding supports the benefit of
prophylactic antibiotics and antenatal corticosteroids in
PPROM as shown in previous studies [8,9].
Since 1998, cases diagnosed as PPROM in our institute
were managed expectantly as per recommendation from
ACOG [10,11]. A 7-day course of parenteral ampicillin
and oral therapy with amoxicillin and erythromycin was
used during expectant management of PPROM hoping
to prolong pregnancy and to reduce infectious and ges-
tational age-dependent neonatal morbidity [9-11].
There have been several studies evaluating prophylactic
antibiotics in PPROM [13-15]. Magwali TL et al. used co-
amoxiclav in their study and found that antibiotics could
prolong latency period and decreased neonatal and mater-
nal morbidity due to sepsis [13]. Ryo E et al. used imipe-
nem/cilastatin sodium in their study and found that
imipenem/cilastatin sodium could prolong the latency
period [14]. August Fuhr N et al. used mezlozillin in their
study and found that antibiotics could prolong latency
period and reduced neonatal infectious morbidity [15].
However, there has been no study evaluating the outcome
of PPROM after the recommendation to use prophylactic
ampicillin and erythromycin.
The usual outcome of PPROM is labor. The latency
period was longer in the study group than in the control
group (3.7 vs. 1.0 days, P < 0.001) which was similar to
previously studies [8,9]. Mercer et al. performed a RCT
study evaluating intravenous ampicillin and erythro-
mycin for 48 hours followed by oral amoxicillin and
erythromycin base for 5 days vs. placebo in PPROM.
They found that antibiotics in the PPROM group had a
longer median time to delivery than the placebo group
(6.1 vs. 2.9 days, P < 0.001) [9]. Kenyon et al. performed
a RCT evaluating erythromycin, co-amoxiclav, both, or
placebo given four times daily for 10 days or until deliv-
ery. They found that the use of erythromycin was asso-
ciated with prolongation of pregnancy in PPROM [8].
This suggests that antibiotics can suppress or prevent
clinically significant intrauterine infection and shorten
latency.
In present study, we found a significant increased
number of patients who did not deliver within 48 hours
and 7 days in study group when compared with acontrol group (64.7% vs. 31.4%, P < 0.001 and 29.4% vs.
7.8%, P = 0.002, respectively). This was similar to previ-
ous reports [8,9]. Mercer et al. found a significantly
decreased number of women assigned to antibiotics
compared with placebo delivered within 48 hours (27.3%
vs. 36.6%, P = 0.03) and delivered within 7 days (55.5%
vs. 73.5%, P = 0.001) [9]. Kenyon et al. demonstrated sig-
nificantly fewer women on erythromycin alone delivered
within 48 hours than did those on placebo (30.5% vs.
40.7%, P < 0.0001) [8].
The maternal infectious morbidity such as chorioam-
nionitis, metritis and wound infection was not different
between groups in the present study. This is in contrast
to previous studies [8,9]. Mercer et al. [9] found that the
antibiotic group had a lower incidence of clinical amnio-
nitis when compared with placebo (23.0% vs. 32.5%;
P = 0.01). But, the incidence of postpartum endometritis
was similar regardless of antibiotic treatment (11.0% vs.
11.5%; P = 0.85). Kenyon et al. [8] found that the use of
both erythromycin and co-amoxiclav (5.0% vs. 8.4%,
P = 0.001) and any antibiotic (6.2% vs. 8.4%, P = 0.008)
was associated with significantly less uterine infection
than use of placebo.
Neonatal infectious morbidity was significantly
decreased in the antibiotic group in the present study.
Mercer et al. found that maternal antibiotic therapy was
associated with reductions in the incidence of neonatal
pneumonia and sepsis in the group B streptococcus
negative cohort [9]. A broad spectrum of aerobic and
anaerobic bacteria and mycoplasmas have been impli-
cated as causative agents for intrauterine infection in
PPROM [16,17]. Thus, broad spectrum antibiotics
(ampicillin plus erythromycin) are more beneficial in this
condition.
The limitation of this study was retrospective study.
We cannot control the confounding factors. Thus, bias
may have been introduced. However, the demographic
characteristics between groups in present study were not
different. Further RCT comparing different regimens of
antibiotics should be conducted.
Conclusions
Latency period of PPROM after using prophylactic anti-
biotics and antenatal corticosteroids increased while
neonatal infectious morbidity was low. But maternal in-
fectious morbidity was not increased. This study con-
firms the benefit of prophylactic antibiotics and
antenatal corticosteroids in management of PPROM.
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